CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Fermer

A new approach for insulin receptor ligand screening

Référence

84900-01

Mots-clés

Insulin

Statut des brevets

French patent application FR0105737 filed on April 27th, 2001 entitled “Méthode de détection de composés activateurs ou inhibiteurs des récepteurs de la famille du récepteur de l’insuline au moyen d’un récepteur chimère isolé” and granted on June 13, 2003.
WO 02 088752 published on November 7, 2002.

Inventeurs

Tarik ISSAD
Nicolas BOUTE
Karine PERNET

Statut commercial

Research agreement, exclusive or non exclusive licences

Laboratoire

Institut Cochin, a CNRS, INSERM and Université Paris 5 laboratory (UMR 8104) in Paris, France.

Description

TECHNICAL DESCRIPTION

This invention involves a procedure based on Bioluminescence Resonance Energy Transfer (BRET) to monitor the activation state of the insulin receptor in vitro. A human insulin receptor with one -beta-subunit fused to Renilla luciferase (Rluc) and the other -beta-subunit fused to the Enhanced Yellow Fluorescent Protein (EYFP) has been developed. The conformational change induced by insulin and other ligands can be detected as an energy transfer (BRET signal) between Rluc and EYFP. BRET signal parallels the effects of the ligands on receptor tyrosine kinase activity. Purified chimeric insulin receptors can be prepared on a large scale and stored at -80 °C for subsequent use. This preparation can be distributed automatically in 96 well microplates and the effect of molecules on insulin receptor activity can be measured in a few minutes with the BRET methodology.

INDUSTRIAL APPLICATION

High-throughput screening test to identify novel molecules with insulin-like activities (Boute et al., 2001, Mol. Pharm. 60, 640-645; Boute et al. TiPS, 23 351-354, 2002).
This assay will be a valuable tool:
– for the discovery of molecules with therapeutic properties, particularly in the field of diabetes and obesity,
– for the discovery of inhibitors with therapeutic properties in the field of IGF1-receptor associated cancers.

For further information, please contact us (Ref 84900-01)

 


Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • This field is for validation purposes and should be left unchanged.
Fermer

Les brevets les plus récents